Barchart on MSN
Should You Buy the Dip in Intellia Therapeutics Stock?
In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with ...
Find out why HDFN should not go untreated, even if it's a mild case, as untreated hemolytic disease can have lasting effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback